Pancreatic Cancer
One of the deadliest major cancers, often diagnosed late; most cases are driven by KRAS mutations.
Coverage of Pancreatic Cancer is holding steady : 5 signals on the latest tracked day, up 25% from its three-week baseline of 4, across 3 domains (unchanged from a week ago). That makes it the #135 most-covered of the 349 concerns we track.
What’s changed
- GenFleet Advances First-in-World KRAS Combination Trial in Pancreatic Cancer - TipRanks · KRAS Mutation Research (Google News) · 2026-08-20
- IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire · KRAS Mutation Research (Google News) · 2026-08-19
- ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer · Annals of Oncology · 2026-08-19
- Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. · Nat Med · 2026-08-11
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. · J Hematol Oncol · 2026-08-08
- Pancreatic Cancer Risk Better Quantified by Features of Pancreatic Cysts · Inside Precision Medicine · 2026-08-21 · usually covers Precision Medicine
What the reporting says
Across 85 tracked stories from 40 outlets, reporting on Pancreatic Cancer most often describes regulatory approvals (12), launches or releases (3), acquisition (2), military action (1), meetings or visits (1).
It shows up alongside KRAS (46), Pdac (13), Colorectal Cancer (11), FDA (16).
Two steps out: Braf (through KRAS, 17 shared stories on the weaker link); AI (through FDA, 16 shared stories on the weaker link); Cder (through FDA, 16 shared stories on the weaker link); Drug Administration (through FDA, 16 shared stories on the weaker link).
Tracked since Mar 12, with coverage on 54 separate days — concentrated in Oncology and Pubmed Targeted.